Best Practices in the Management of Advanced Renal Cell Carcinoma (RCC): Expert Perspectives on Novel Therapies

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2020 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from February 1, 2021 to March 1, 2022

 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from
Exelixis and Merck Sharp & Dohme Corp.

Description:
Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport waste molecules from the blood to the urine. RCC is the most common type of kidney cancer in adults, responsible for approximately 90–95% of cases. In 2020, it is estimated that there will be approximately 73,750 new cases of kidney cancer, and about 14,830 people will die from the disease. Approximately 16% of patients with RCC will have metastases at diagnosis, and as many as 40% will demonstrate metastasis after primary surgical treatment for localized RCC. With a 5-year survival rate ranging from 5% to 12%, the prognosis for these patients is poor. Fortunately for patients with advanced RCC, several new treatments, including targeted therapies and immunotherapies, have recently become available giving clinicians new options to improve patient outcomes and quality of life. Additionally, new combination regimens comprised of multiple receptor tyrosine kinase inhibitors and anti-PD-1 immunotherapies have shown improved efficacy and safety in clinical trials. With so many new options becoming available for the healthcare community, clinicians are struggling to stay abreast of all the changes in advanced RCC treatment. It is critical that medical directors, oncologists, nurses and other healthcare professionals are updated on these emerging options and strategies for implementing them into the treatment paradigm, which will ultimately improve patient outcomes.

The prognosis for any treated renal cell cancer patient with progressing, recurring, or relapsing disease is poor, regardless of cell type or stage. Almost all patients with advanced renal cell cancer are incurable. The question and selection of further treatment depends on many factors, including previous treatment and site of recurrence, as well as individual patient considerations. Fortunately, clinicians have recently been equipped with more options to integrate into the advanced RCC treatment paradigm, including targeted therapies and immunotherapies, which individualize therapy for patients with advanced RCC who have progressed on prior therapies, ultimately improving patient outcomes and quality of life. Additionally, multiple receptor tyrosine kinase inhibitors and anti-PD-1 immunotherapies have been combined in clinical trials with impressive results. These new options have shown improved efficacy and safety in advanced RCC, and medical directors, oncologists, nurses and other healthcare professionals must be educated on these options and the potential risks that come along with any new treatment option.

Upon completion of this activity, participants will be able to:

  • Identify current unmet economic and clinical needs in the management of advanced renal cell carcinoma (RCC) and evidence-based recommendations for the care of patients with these tumors

  • Examine the pathogenesis of RCC and the scientific foundation for targeted therapies

  • Analyze recent efficacy and safety data on single-agent and combination targeted therapies and immunotherapies, as well as patient and disease characteristics and patient preferences, as a part of shared decision-making for patients with advanced RCC

  • Examine the role of targeted therapies and immunotherapies in the first-line management of advanced RCC

  • Explore strategies to monitor and manage adverse events associated with targeted therapy and immunotherapy options in advanced RCC in order to improve patient adherence and quality of life

  • Discuss the managed care considerations of current and emerging targeted therapies and immunotherapies by exploring where these agents fit into the current advanced RCC management paradigm

     

Faculty: Robert A. Figlin, MD, FACP
Steven Spielberg Family Chair in Hematology Oncology
Professor of Medicine and Biomedical Sciences
Deputy Director, Cedars-Sinai Cancer
Deputy Director, Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center

Disclosure:

Dr. Figlin serves on an advisory board for Appolomics, Eisai, Exelixis and Merck. He has received grant/research support from Calithera, Exelixis and Merck. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by educational grants from
Exelixis and Merck Sharp & Dohme Corp.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue